Copyright © Inderes 2011 - present. All rights reserved.

Herantis Pharma

1.98 EUR

+1.54 %

4,542 following
Corporate customer

HRTIS

First North Finland

Biotechnology & Pharmaceuticals

Health Care

+1.54 %
-20.48 %
-2.94 %
-8.76 %
+2.59 %
+34.24 %
-20.16 %
-56.63 %
-80.34 %

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Read more
Market cap
51.35M EUR
Turnover
62.81K EUR
P/E (adj.) (25e)
-7.94
EV/EBIT (adj.) (25e)
-8.94
P/B (25e)
-36.56
EV/S (25e)
4,926.3
Dividend yield-% (25e)
-
Coverage
Recommendation
Reduce
Target price
2.50 EUR
Updated
08.01.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 09.01.2026

Latest extensive report

Released: 22.12.2025

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5.3
2026

Annual report '25

23.4
2026

General meeting '26

20.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Herantis now has a very substantial dataset at its disposal regarding these biomarkers, and its more detailed analysis will take some time. What I personally paid attention to in that presentation was that the data also showed changes in blood samples (as I recall, this was related...
1/9/2026, 8:42 AM
by jerej
18
Discovery made at the University of Helsinki in the early 2000s – now drug developer aims to stop Parkinson’s disease with it | Uusimaa | Yle
1/31/2026, 5:10 PM
by Alamäki
11
Here are Antti’s comments on how Herantis successfully executed a directed share issue Herantis announced late on Wednesday that it has successfully completed a EUR 4.2 million directed share issue. The funding will be used to prepare for the Phase II study of the HER-096 drug candidate...
2/12/2026, 9:10 AM
by Sijoittaja-alokas
9
14th Alzheimer's & Parkinson's Drug Development Summit Full Event Guide Discover the Full Event Guide to plan your participation in expert talks and interactive sessions on neuro-degenerative care and research. HER-096 has been in good company; I wonder how full the room was for ...
2/7/2026, 8:22 AM
9
Very relieving news regarding the share issue. Investors have clear confidence in Herantis, in contrast to the ongoing “share issue crisis” at Faron. With the offering, Herantis can steadily continue its work for the benefit of Parkinson’s patients.
2/12/2026, 2:31 AM
by Alamäki
7
Financing, i.e. a directed issue. €4.2M, €1.75/share. Tärkeimmät talousuutiset | Kauppalehti – 11 Feb 26 Sisäpiiritieto: Herantis Pharma Oyj toteuttaa onnistuneesti suunnatun... Tärkeimmät ajankohtaiset talousuutiset, pörssikurssit ja kattavat sijoittajapalvelut löydät Kauppalehdest...
2/11/2026, 11:57 PM
by WilunGi
4
Thank you. This trend may also have some impact on the future of the drug development companies discussed on this forum.
1/27/2026, 5:21 AM
by Timo Rousi
4
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.